Akorn, Hi-Tech Pharmacal settle with FTC over merger
MLex Summary: Akorn, Hi-Tech Pharmacal has reached a settlement agreement with the US Federal Trade Commission resolving charges that their proposed $640 million merger is anticompetitive. The agency requires the companies to sell the...To view the full article, register now.
Already a subscriber? Click here to view full article